{"filing":{"accession_number":"0001628280-26-039518","cik":"0001434868","ticker":"ESPR","company_name":"Esperion Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-01","report_date":null,"primary_document":"espr-20260528.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828026039518/espr-20260528.htm"},"events":[{"id":7962,"run_id":6991,"accession_number":"0001628280-26-039518","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Esperion held its Annual Meeting of Stockholders on May 28, 2026, with shareholders voting on four proposals: election of two Class I directors (J. Martin Carroll and Sheldon L. Koenig), an advisory vote on named executive officer compensation, ratification of Ernst \u0026 Young LLP as auditor, and approval of a 7,000,000 share increase to the 2022 Stock Option and Incentive Plan. Vote tallies for each proposal are disclosed.","company_name":"Esperion Therapeutics, Inc.","ticker":"ESPR","filing_date":"2026-06-01","form":"8-K","submitted_at":null,"items":[{"id":3357,"accession_number":"0001628280-26-039518","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure reports stockholder approval of an amendment to the 2022 Stock Option and Incentive Plan increasing authorized shares by 7,000,000 shares. This is a compensation plan amendment affecting the pool of equity available for executive and employee grants, which is a material disclosure under Item 5.02(e) regarding compensation arrangements. The amendment directly impacts the registrant's ability to grant future equity compensation.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T03:08:42.356506+00:00","company_name":"","ticker":null,"filing_date":""},{"id":3358,"accession_number":"0001628280-26-039518","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from Esperion's Annual Meeting held May 28, 2026, covering four proposals: election of two Class I directors (J. Martin Carroll and Sheldon L. Koenig), advisory vote on named executive officer compensation, ratification of Ernst \u0026 Young LLP as auditor, and approval of a 7,000,000 share increase to the 2022 Plan. The filing provides vote tallies (For, Against, Abstain, Broker Non-Votes) for each proposal, which is the standard format for Item 5.07 shareholder vote results disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T03:08:42.356506+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3357,"accession_number":"0001628280-26-039518","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure reports stockholder approval of an amendment to the 2022 Stock Option and Incentive Plan increasing authorized shares by 7,000,000 shares. This is a compensation plan amendment affecting the pool of equity available for executive and employee grants, which is a material disclosure under Item 5.02(e) regarding compensation arrangements. The amendment directly impacts the registrant's ability to grant future equity compensation.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T03:08:42.356506+00:00","company_name":"Esperion Therapeutics, Inc.","ticker":"ESPR","filing_date":"2026-06-01"},{"id":3358,"accession_number":"0001628280-26-039518","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from Esperion's Annual Meeting held May 28, 2026, covering four proposals: election of two Class I directors (J. Martin Carroll and Sheldon L. Koenig), advisory vote on named executive officer compensation, ratification of Ernst \u0026 Young LLP as auditor, and approval of a 7,000,000 share increase to the 2022 Plan. The filing provides vote tallies (For, Against, Abstain, Broker Non-Votes) for each proposal, which is the standard format for Item 5.07 shareholder vote results disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T03:08:42.356506+00:00","company_name":"Esperion Therapeutics, Inc.","ticker":"ESPR","filing_date":"2026-06-01"}]}